Mubasher: Dubai-based Bioventure, Minapharm Pharmaceuticals, and MiGenTra GmbH have signed an exclusive licence agreement for the commercialisation of multiple biosimilar candidates developed and manufactured by Alvotech, in Egypt and eighteen additional countries in Africa and the Middle East (the Territory).
As per the deal, Egypt’s Minapharm Pharmaceuticals and Berlin-based MiGenTra GmbH will share responsibilities in the Territory to file, launch, and commercialise Alvotech's portfolio of licenced biosimilars once approved, under Bioventure's exclusive strategic partnership with Alvotech in the region, according to a press release on Tuesday.
Wafik Bardissi, CEO of Minapharm Pharmaceuticals, commented: "This standout agreement with Bioventure enables selected Alvotech products to boost our regional and continental strategy and elevates access to complex medicines."
Lutz Hilbrich, CEO of MiGenTra GmbH, said: "This agreement with Bioventure will allow MiGenTra to provide patients across Africa and the Middle East with a unique set of high quality and affordable biological medicines by combining in-house developed biosimilars with Alvotech's highly complementary candidates."
Licenced biosimilar candidates cover a wide range of therapeutic areas, all characterised by a high unmet medical need in the Territory.
